TABLE 1.
Summary statistics for the six datasets included in this study
| Braak(Tau) |
CDR |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Condition | N | Agea | %Fe | %APOE4+ | 0–III | IV–VI | Not avail. | < = 0.5 | 1–2 | 3 | PMI | ||
| Discovery | WUSM (parietal brain) | ADAD | 25 | 54 ±13.9 | 32% | 36% | 0 | 20 | 5 | 0 | 0 | 25 | 13.3 |
| sAD | 305 | 84 ± 8.8 | 62% | 56% | 23 | 195 | 87 | 0 | 23 | 282 | 12.5 | ||
| TREM2 | 21 | 84 ± 7.5 | 52% | 57% | 3 | 12 | 6 | 0 | 1 | 20 | 14.1 | ||
| Presymptomatic | 15 | 87 ± 9.7 | 60% | 53% | 3 | 8 | 4 | 15 | 0 | 0 | 13.6 | ||
| Control | 26 | 88 ±9.1 | 69% | 12% | 20 | 1 | 5 | 26 | 0 | 0 | 10.0 | ||
| Replication | ROSMAP (DLPFC brain Metabolon) | sAD | 233 | 89 ±2.9 | 73% | 38% | 15 | 218 | 0 | 8.1 | |||
| Control | 94 | 86 ± 4.7 | 59% | 10% | 94 | 0 | 0 | 7.7 | |||||
| ROSMAP (DLPFC brain p180) | sAD | 43 | 88 ± 2.8 | 19% | 29% | 3 | 40 | 0 | 9.6 | ||||
| Control | 23 | 87 ± 3.8 | 35% | 7% | 23 | 0 | 0 | 8.7 | |||||
| ROSMAP (serum) | sAD | 36 | 87 ± 3.8 | 81% | 8% | ||||||||
| Control | 55 | 87 ± 4.4 | 69% | 0% | |||||||||
| ADNI1 (serum) | sAD | 184 | 75 ± 7.5 | 48% | 66% | ||||||||
| Control | 224 | 76 ± 5.0 | 48% | 27% | |||||||||
| ADNIGO/2 (serum) | sAD | 137 | 74 ± 8.2 | 42% | 66% | ||||||||
| Control | 181 | 73 ± 6.4 | 51% | 28% | |||||||||
Abbreviations: CDR, Clinical Dementia Rating; PMI, post mortem interval; sAD, sporadic Alzheimer’s disease.
a
Age is age at death for brain samples, and age at baseline for serum samples.